Welcome to the Hope Bio Blog

FOR IMMEDIATE RELEASE By Jan Shultis Sugar Land, Texas, 3 February 2026 - A multicenter trial stretching across the southwestern United States is now recruiting patients to investigate whether allogeneic (donor-derived) Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) can prevent progression of trauma-induced Acute Kidney Injury (AKI), an abrupt decline in renal function that occurs over hours to days in up to 50% of trauma and burn patients and has few eff

Happy, happy 2026, Hope community! One of our favorite parts of welcoming a new year is to reflect on the period concluding. There are many ways to present annual reviews, and in the near-decade since our founding we have tried many, from formal materials and presentations to stakeholder reports. This year, however, we’re trying something new – we want to celebrate the year with those who made it possible, in plain language. We want to celebrate with you. If you prefer to

Inspired by results in other autoimmune conditions By Jan Shultis Billions of stem cells manufactured through proprietary technology by Houston-area biotechnology company Hope Biosciences have the regulatory “green light” to join the fight against Crohn’s Disease. The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disea